Wall Street analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to post sales of $29.80 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with estimates ranging from $21.66 million to $37.09 million. Lexicon Pharmaceuticals reported sales of $23.04 million in the same quarter last year, which suggests a positive year over year growth rate of 29.3%. The business is expected to issue its next quarterly earnings results on Friday, March 2nd.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full year sales of $29.80 million for the current financial year, with estimates ranging from $78.94 million to $94.37 million. For the next year, analysts forecast that the business will post sales of $122.05 million per share, with estimates ranging from $110.64 million to $129.40 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Lexicon Pharmaceuticals.
LXRX has been the topic of several recent research reports. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Wedbush reissued an “outperform” rating and issued a $38.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Thursday, November 30th. ValuEngine cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Finally, BidaskClub raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 20th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $28.50.
Large investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth $182,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth $117,000. Cubist Systematic Strategies LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth $149,000. Aperio Group LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth about $127,000. Finally, C WorldWide Group Holding A S boosted its position in shares of Lexicon Pharmaceuticals by 49.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 16,146 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 5,353 shares in the last quarter.
Lexicon Pharmaceuticals (NASDAQ LXRX) opened at $9.24 on Tuesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65. The stock has a market cap of $980.91, a price-to-earnings ratio of -7.33 and a beta of 0.24. Lexicon Pharmaceuticals has a 12 month low of $8.07 and a 12 month high of $18.00.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.